Bioporto A/S
CSE:BIOPOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioporto A/S
Operating Expenses
Bioporto A/S
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Operating Expenses
-kr116.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-15%
|
|
|
Genmab A/S
CSE:GMAB
|
Operating Expenses
-kr2.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-43%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Expenses
-kr2.1B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-24%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Operating Expenses
-$16.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Expenses
-€761.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-31%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Expenses
-kr1.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-8%
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Operating Expenses?
Operating Expenses
-116.5m
DKK
Based on the financial report for Dec 31, 2025, Bioporto A/S's Operating Expenses amounts to -116.5m DKK.
What is Bioporto A/S's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-15%
Over the last year, the Operating Expenses growth was -17%. The average annual Operating Expenses growth rates for Bioporto A/S have been -6% over the past three years , -9% over the past five years , and -15% over the past ten years .
